Bio-Techne

Spear Bio is a biotechnology company established in 2021 and located in Weston, Massachusetts. The company specializes in ultrasensitive protein detection technology, which provides significant advantages in the healthcare sector. Its innovations support self-testing and telemedicine-based diagnostics by enabling the quantification of minute protein biomarkers from samples collected at home. This approach allows clinicians to achieve ultrasensitive detection using small sample volumes, seamlessly integrating into existing workflows for sample collection, processing, and analysis.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Wilson Wolf Corporation, founded in 1998, specializes in the design and manufacture of innovative cell culture devices aimed at advancing healthcare solutions. The company develops a range of products for diverse applications such as monoclonal antibody production, living skin, corneal storage, islet transplants for type 1 diabetes, and immunotherapy. Their revolutionary gas permeable cell culture device platform serves as an alternative to traditional methods like plates, flasks, and bags, providing enhanced options for scientists and businesses engaged in cell culture. Wilson Wolf is committed to contributing to medical advancements, particularly in cancer treatment and regenerative medicine.

Namocell Inc. is a biotechnology firm based in Mountain View, California, that specializes in the development, manufacture, and distribution of microfluidic-based platforms for single-cell enrichment, sorting, and analysis. Founded in 2014, the company focuses on applications in life science research and clinical settings, including cell line development, cancer diagnostics, and immunotherapy. Namocell's innovative single-cell dispensers enable researchers to efficiently identify and isolate individual cells while maintaining their viability and integrity. Their technology serves a diverse range of applications, such as CRISPR and induced pluripotent stem cell cloning, single-cell genomics, cell and gene therapy, antibody discovery, rare cell isolation, and synthetic biology.

Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, focused on providing patient management solutions for oncology and genetic disorders. Founded in 2005, Asuragen develops and commercializes diagnostic products for clinical laboratories and biopharma partners. Its product portfolio includes the AmplideX FMR1 PCR reagents for detecting CGG repeats in the fragile X mental retardation gene, various cancer testing kits like QUANTIDEX, and the Signature technology for multiplex analysis of nucleic acid sequences, which includes assays for mutations in KRAS and BRAF genes. In addition to these diagnostic tools, Asuragen offers GLP testing services, cGMP manufacturing capabilities, and expertise in biomarker discovery and regulatory processes. This integrated approach facilitates the development, testing, and commercialization of diagnostic solutions aimed at improving treatment outcomes in oncology and genetic conditions.

Eminence developing and manufacturing CHO chemically-defined media, and providing cell line and media formulation development services. Eminence has developed EmCD CHO® basal medium and EmCD CHO® Feed for CHO-K1, CHO-S, CHO-DG44 and other cell lines. Eminence offers a wide range of tailor-made services including medium formulation development/optimization and media production to cater to individual customers' diverse needs. With an experienced R&D and production team, Eminence owns GMP-compliant medium production plants and state-of-the-art labs to provide best-of the-breed products and flexible services for customers, while helping biopharma companies comply with the increasingly stringent requirements for safety and effectiveness in the biopharma industry.

B-MoGen Biotechnologies Inc is a genome engineering startup located in Minneapolis, Minnesota. Founded in 2015, B-MoGen has entered strategic partnerships with biotechnology companies, completed projects for clients in academia and industry, and successfully licensed and developed novel intellectual property focused on genome engineering. B-MoGen Biotechnologies Inc offers custom tools for gene delivery and gene editing.

Exosome Diagnostics, Inc. specializes in the development and commercialization of biofluid-based molecular diagnostic tests aimed at enhancing personalized precision healthcare. The company employs a proprietary exosome technology platform that extracts and analyzes molecular information from exosomes present in various biofluids, including blood, urine, and cerebrospinal fluid. This approach enables non-invasive diagnostics for serious diseases, significantly reducing the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously analyzes exosomal RNA and circulating tumor DNA in a single assay to identify actionable mutations across multiple cancer types. By combining RNA, DNA, and protein analysis, Exosome Diagnostics provides comprehensive molecular insights that can transform the detection, diagnosis, treatment, and monitoring of cancer and other serious conditions. The company also collaborates with pharmaceutical firms to enhance research and development processes, including biomarker discovery and the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, Exosome Diagnostics operates as a subsidiary of Bio-Techne Corporation.

Quad Technologies is disrupting cell separation and cell therapy workflows by providing researchers with a simple, cell-friendly capture and release technology for cell isolation. Their new MagCloudz™ Streptavidin Cell Separation kit, featuring novel QuickGel™ technology platform, enables straightforward, scalable and fast cell separation with unique magnetic particle dissociation, resulting in complete label free cells. For applications such as T Cell purification, stem cell isolation, circulating tumor cell (CTC) separation and immunotherapy, this unique solution offers drastically improved cell viability, purity and recovery while maintaining a native cellular phenotype.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

Space Import Export S.r.l. is a distribution company that has been working in the Life Science business since 1985, specialized in the fields of Biomedical Research and Diagnostic Market. Our distribution activity has grown, through an active cooperation with a sister company, called LaboSpace, provider of laboratory services, with branches in Italy, UK and USA.

Zephyrus Biosciences provides research tools to enable protein analysis at the single-cell level. Addressing the burgeoning single-cell analysis market, our first product, the scWestern system, enables western blotting on individual cells for the first time. Researchers will utilize Zephyrus’s products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development. It was founded in 2013 and headquartered in Berkeley, California.

CLINIQA Corp specializes in the manufacturing and commercialization of quality controls and calibrators for the in vitro diagnostics (IVD) industry. With over 40 years of experience, the company has established a reputation for producing high-quality products that enhance the accuracy of diagnostic tests. CLINIQA operates from facilities in San Diego County, California, and adheres to stringent quality management systems that comply with FDA regulations and international standards. The company offers a range of products, including reagents, controls, calibrators, proficiency test materials, and contract manufacturing services. Notably, its Liquid QC® products provide "ready-to-use" solutions with extended shelf life and stability, addressing market demands for convenience and reproducibility. CLINIQA's commitment to quality and focus on liquid stabilization technology underpins its success in meeting the needs of the diagnostic sector.

CyVek, Inc. is a biotechnology company based in Wallingford, Connecticut, established in 2008. The company specializes in developing a technology platform designed for measuring analytes in biological samples. CyVek offers an integrated test system that features a microfluidic cartridge, enabling the analysis of multiple biomarkers from minimal quantities of biological materials. This innovative approach facilitates efficient and accurate testing, supporting advancements in diagnostics and research.

The mission of Novus Biologicals, LLC is to accelerate scientific discovery by developing and marketing unique products for the lifesciences. Novus Biologicals is also organized to provide the biological research community with a mechanism for commercializing unique biological materials. We also focus on continually monitoring scientific trends and supply materials to serve these trends. By making these products widely available to institutional and commercial researchers, Novus Biologicals plays an important role in furthering biological research. All of Novus Biologicals products are supplied with detailed technical information and ongoing support. By serving both niche and emerging markets, Novus Biologicals has built solid partnerships with our customers.

ProteinSimple, part of the Protein Platforms division of Bio-Techne, specializes in innovative protein analysis tools that assist researchers in understanding proteins and their roles in disease. The company offers a diverse range of products, including immunoassay systems for quantifying protein expression and systems designed to assess the structure and purity of protein-based therapeutics. Their nano-proteomic analysis systems focus on resolving protein analysis issues, enabling life science researchers to measure phosphor-protein signaling and activation in small biological samples. These tools allow for the quantification of phosphor-protein isoforms in various cell types, including primary and sorted stem cells, and facilitate the monitoring of drug actions in tissue sections and fine needle aspirates. ProteinSimple's solutions are vital for advancing research in the life sciences globally.

Shanghai PrimeGene Bio-Tech Co is a prominent company based in Shanghai, China, specializing in the development, manufacture, and distribution of recombinant proteins for research and diagnostic applications. The company provides a wide array of high-quality recombinant proteins and associated antibodies tailored for bio-reagent companies. Its product offerings include recombinant proteins, recombinant antigens for diagnostics, protein A, protein G, protein L, monoclonal antibodies, protein standard markers, and services related to gene cloning, synthesizing, and gene expression in E. coli and yeast systems. Through its focus on quality and innovation, Shanghai PrimeGene Bio-Tech Co plays a significant role in advancing diagnostic research in the biotechnology sector.

CyVek, Inc. is a biotechnology company based in Wallingford, Connecticut, established in 2008. The company specializes in developing a technology platform designed for measuring analytes in biological samples. CyVek offers an integrated test system that features a microfluidic cartridge, enabling the analysis of multiple biomarkers from minimal quantities of biological materials. This innovative approach facilitates efficient and accurate testing, supporting advancements in diagnostics and research.

Bionostics is a world-leading developer and manufacturer of high quality, turnkey calibrators and quality control products for original equipment manufacturers (OEMs) for critical care / point-of-care and diabetes diagnostics test systems. Located in Devens, Massachusetts, Bionostics offers a variety of services to provide high quality, cost effective, turn-key solutions to our customers, large and small. We maintain professional associations with customers and suppliers, striving to work together in relationships that are beneficial for all parties. As a key partner to world-class OEMs, we are acutely aware of our responsibility to maintain and foster the brand identities of our clients. Our quality systems are certified to ISO 9001:2008 and 13485:2003. Our products are listed as Class I and Class II with the US FDA, bear Class II and Class III Medical Device Licenses in Canada and fully comply with requirements of 98/79/EC, the In-Vitro Diagnostics Directive.

Tocris Holdings is a supplier of reagents for non-clinical life science research.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focused on developing and commercializing innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company's lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently undergoing Phase III trials for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and a Phase IIb trial for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing other drug candidates, including CCX140, an inhibitor targeting the CCR2 chemokine receptor, which has completed Phase II trials for diabetic nephropathy and is being developed for focal segmental glomerulosclerosis; CCX507, a second-generation CCR9 inhibitor that has completed Phase I trials; and CCX872, a selective CCR2 inhibitor currently in Phase Ib trials for stage 3 and 4 pancreatic cancer. ChemoCentryx aims to address the underlying immune system dysfunction associated with various conditions through its targeted therapeutics.